Researchers have developed a Dp44mT nano-carrier that can directly target glioblastoma and other brain cancer cells.
Treating mouse models of astrocytomas with a new combination therapy resulted in tumor regression in 60% of the mice.
Disabling the CD161 pathway restores the T-cell’s ability to attack gliomas and extends lifespan in animal models of brain cancer.
A new zebrafish model holds the potential for future studies of glioblastoma, an aggressive and lethal brain cancer.
Study reveals a detailed map of gene proteins, infiltrating cells, and signaling pathways that play significant roles in the development and progression of glioblastoma brain cancer.
Inhibiting the SCD enzyme and blocking the function of FOSB blunts acquired drug resistance and improves survival in mouse models of glioblastoma brain cancer.
Researchers discovered all neuroblastomas arise from a single type of embryonic cell called sympathoblasts. The findings could lead to new avenues of treatment for the aggressive childhood cancer.
Researchers have identified a pathway involving a protein called Rab35 in glioblastoma brain cancer. The study reports restoring the activity of Rab35 could have therapeutic benefits for those with glioblastoma.
20% of glioblastoma brain cancers are fueled by overactive mitochondria. Researchers say these cases may be treatable by drugs currently under trial.
Mindfulness-based stress reduction can help reduce symptoms of neuropathic pain in ****** cancer survivors.